Navin Fluorine International posts FY26 results, announces dividend
Navin Fluorine International filed its Integrated Annual Report for FY 2025-26, reporting a 129.94% YoY increase in net profit to ₹663.55 crores and a 41.05% rise in revenue to ₹3,313.90 crores. The Board recommended a final dividend of ₹8.60 per share, with the 28th AGM scheduled for August 06, 2026 via video conferencing. The company raised ₹750 crores via QIP, commissioned new facilities, and improved ESG metrics including a 12.15% renewable electricity usage.

*this image is generated using AI for illustrative purposes only.
Navin Fluorine International Limited has filed its Integrated Annual Report for FY 2025-26 with the stock exchanges, detailing a financial performance marked by six consecutive quarters of growth. The report covers the financial year ended March 31, 2026 and includes the Notice of the 28th Annual General Meeting scheduled for August 06, 2026 at 3.30 P.M. (IST) via Video Conferencing/Other Audio-Visual Means. The company reported a 129.94% YoY surge in net profit to ₹663.55 crores, while revenue from operations increased 41.05% to ₹3,313.90 crores.
AGM and Dividend Details
The Board of Directors has recommended a final dividend of ₹8.60 per equity share of face value ₹2/- each (430% of face value) for FY 2025-26, subject to member approval at the AGM. An interim dividend of ₹6.50 per equity share (325% of face value) was already paid in November 2025. Key AGM-related dates are summarised below:
| Parameter: | Details |
|---|---|
| AGM Date and Time: | Thursday, August 06, 2026 at 3.30 P.M. (IST) |
| Mode: | Video Conferencing (VC) / Other Audio-Visual Means (OAVM) |
| Final Dividend Record Date: | June 12, 2026 |
| Final Dividend Payment Date: | On or after August 13, 2026 |
| E-Voting Cut-off Date: | July 30, 2026 |
| E-Voting Start: | August 01, 2026 (9:00 A.M. IST) |
| E-Voting End: | August 05, 2026 (5:00 P.M. IST) |
Financial Performance Highlights
Operating EBITDA reached ₹1,081.68 crores, registering 102.67% YoY growth, with margins expanding to 32.64%. Consolidated net worth increased by 51.34% from ₹2,626.23 crores as of March 31, 2025 to ₹3,974.58 crores as of March 31, 2026. The company maintained a credit rating of 'CARE AA' for long-term borrowings and 'CARE A1+' for short-term facilities.
| Metric: | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenues from Operations: | ₹3,313.90 crores | ₹2,349.38 crores |
| Operating EBITDA: | ₹1,081.68 crores | ₹533.72 crores |
| Operating EBITDA Margin: | 32.64% | 22.72% |
| Net Profit: | ₹663.55 crores | ₹288.60 crores |
| Net Profit Margin: | 20.02% | 12.28% |
| Return on Capital Employed: | 25.92% | — |
| Net Debt/Equity: | 0.01x | — |
| Operating Cash Flow: | ₹893.57 crores | — |
Business Vertical Performance
All three business segments recorded strong double-digit revenue growth during the year. The HPP business commissioned the new AHF facility at Dahej involving an investment of ₹450 crores, and the Board approved a capital expenditure of ₹236.50 crores for an additional HFC capacity of 15,000 MTPA equivalent R32 refrigerant.
| Business Vertical: | Revenue (₹ crores) | YoY Growth | Share of Total Revenue |
|---|---|---|---|
| High Performance Products (HPP): | 1,615.38 | 33.93% | ~48.75% |
| Specialty Chemicals: | 1,152.09 | 43.94% | 34.76% |
| CDMO: | 546.43 | 59.39% | 16.49% |
The Specialty Chemicals business entered into a strategic partnership with Chemours to manufacture Opteon™, a two-phase immersion cooling fluid for hyper data centres, with a total estimated capex outlay of US$ 14 million. The facility is expected to be operational in Q1 FY 2026-27. The CDMO business successfully commissioned the cGMP4 Phase 1 facility, with commercial supplies commencing from January 2026. The subsidiary Navin Fluorine Advanced Sciences Limited (NFASL) achieved total revenue from operations of ₹1,133.56 crores, EBITDA of ₹408.35 crores and PBT of ₹225.21 crores for FY 2025-26.
Capital Raise and Balance Sheet Strengthening
During the year, the company successfully raised ₹750 crores through a Qualified Institutional Placement (QIP), allotting 16,02,564 equity shares of ₹2/- each to eligible Qualified Institutional Buyers at an issue price of ₹4,680/- per equity share. The proceeds were primarily utilised for repayment/pre-payment of outstanding borrowings of Navin Fluorine and NFASL, and general corporate purposes. Working capital days were reduced from 89 to 74 days (Sales), and market capitalisation stood at ₹31,581.93 crores as on March 31, 2026.
Operational and ESG Highlights
Total R&D spend for FY 2025-26 stood at ₹48.71 crores. The company executed 28 focused energy efficiency and water efficiency projects, resulting in savings of 62,283.16 GJ of energy and 1,53,850.92 KL of water savings. Internal energy and water efficiency projects delivered over ₹7.65 crores in annual savings.
| ESG Indicator: | FY 2025-26 Value |
|---|---|
| Renewable Electricity Usage: | 12.15% of total electricity consumption |
| Total Energy Conserved: | 62,283.16 GJ |
| Water Recycled/Reused: | 6,85,418.00 KL (54.31% of total withdrawal) |
| Total Waste Recycled/Reused: | 87,902.03 MT (65.76% of generation) |
| Scope 1 + 2 GHG Emissions: | 2,39,549.27 tCO₂e |
| Total CSR Spend: | ₹7.50 crores (mandatory: ₹6.47 crores) |
| Total Employees: | 1,569 permanent employees |
| Attrition Rate: | 14.60% |
| Average Training Hours per Employee: | 27.36 |
Historical Stock Returns for Navin Fluorine International
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.20% | +3.67% | +4.76% | +23.99% | +50.25% | +98.37% |
How will the strategic partnership with Chemours for Opteon™ production impact Navin Fluorine's market share in the data center cooling sector once the facility becomes operational in Q1 FY 2026-27?
With the company maintaining a near-zero net debt-equity ratio, will the increased financial flexibility lead to higher dividend payouts or accelerated capital expenditure in the coming fiscal year?
Can the CDMO segment sustain its 59.39% revenue growth rate following the commissioning of the cGMP4 Phase 1 facility, or will growth normalize as commercial supplies scale up?































